Alnylam to move away from service-based research as Novartis cuts loose
This article was originally published in Scrip
Executive Summary
The five-year long RNAi-based research collaboration between Alnylam Pharmaceuticals and Novartis has come to an end, with the result that Alnylam is restructuring its operations "from a position of strength" with the intention of moving away from service-based research towards "higher value activities such as advancing our own pipeline", said chief executive Dr John Maraganore.